Persons living with <scp>HIV</scp> with advanced <scp>HIV</scp> disease: need for novel care models

Chloe A. Teasdale, Katharine A. Yuengling, Peter Preko, Maureen Syowai, Felix Ndagije, Miriam Rabkin, Elaine J. Abrams, Wafaa El‐Sadr

Journal of the International AIDS Society · 2018 · 20 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

Abstract Introduction Despite increasing focus on test and treat strategies for people living with HIV ( PLHIV ), many continue to enrol late in care and initiate antiretroviral therapy ( ART ) when they have advanced HIV disease. Methods We analyzed PLHIV ≥15 years of age starting ART in Ethiopia, Kenya, Mozambique and Tanzania from 2005 to 2015 based on CD 4+ groups at ART initiation (≥200, 100 to 199, 50 to 99 and &lt;50 cells/mm 3 ) to examine attrition (loss to follow‐up ( LTF ) and death) using Kaplan‐Meier estimators and Cox proportional hazards models. LTF was defined as no clinic visit &gt;6 months; deaths were ascertained from medical records. Results and discussion A total of 305,443 PLHIV were included in the analysis: 118,580 (38.8%) CD 4+ ≥200, 91,788 (30.1%) CD 4+ 100 to 199, 44,029 (14.4%) CD 4+ 50 to 99 and 51,046 (16.7%) CD 4+ &lt;50 cells/mm 3 . At 12 months after ART initiation, attrition for those with CD 4+ ≥200, 100 to 199, 50 to 99 and &lt;50 cells/mm 3 was 21.3% (95% CI 21.1 to 21.6), 21.8% (95% CI 21.6 to 22.1), 27.3% (95% CI 26.9 to 27.7) and 33.6% (95% CI 33.2 to 34.0) respectively. In multivariable models, compared to PLHIV with CD 4+ ≥200 cells/mm 3 , those with CD 4+ 50 to 99 cells/mm 3 had 29% increased risk of attrition (adjusted hazard ratio ( AHR ) 1.29, 95% CI 1.27 to 1.32) and those with &lt;50 cells/mm 3 had 56% increased risk of attrition ( AHR 1.56, 95% CI 1.53 to 1.58). Men had higher attrition compared to women across all CD 4+ groups and overall were 28% more likely to experience attrition ( AHR 1.28, 95% CI 1.26 to 1.29). Even after ART initiation, PLHIV with advanced disease had notably inferior outcomes with substantial gradient within the low CD 4+ strata highlighting the need for targeted interventions for these populations. Conclusions Greater efforts, including the identification of effective differentiated service delivery models, are needed to ensure that all PLHIV starting treatment can garner the benefits from ART and achieve favourable outcomes.

References

24